Efficacy of Injectable Collagenase in the Treatment of Dupuytren's Contracture in Comparison to Partial Fasciectomy | ||
| The Egyptian Journal of Plastic and Reconstructive Surgery | ||
| Article 6, Volume 43, Issue 2, July 2019, Pages 191-195 PDF (7.96 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejprs.2019.64914 | ||
| Authors | ||
| Mohamed Elrouby* ; Ahmed Abdelsalam; Ahmed Gad; Khaled Rizq | ||
| The Department of Plastic Reconstructive & Maxillofacial Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt | ||
| Abstract | ||
| Background: Dupuytren's disease as a benign fibroproliferative disease with an abnormal slowly progressive thickening and shorting of the palmar aponeurosis leads to severe functional limitations in the finger movements particularly of the Metacarpophalangeal (MCP) joints and/or the Proximal Interphalangeal (PIP) joints. The authors aimed to evaluate the role of injectable collagenase (CCH) in the treatment of Dupuytren's contracture in comparison to surgical treatment. Material and Methods: This study included 15 patients (33 rays), they were divided into two groups, Group A: 26 rays underwent open fasciectomy. (10 patients) and Group B: 7 rays were treated by collagenase injection. (5 patients). Exclusion criteria for group B were contraindications of injection of CCH. The primary efficacy variable was clinical success, contracture correction to within 5º of normal (normal =0º) by using goniometry. Additional efficacy variables included the time and number of injections required to achieve success in the primary joint. Recurrence rate and adverse effects were recorded. Results: Initial clinical experience was recorded of 5 patients (7 rays) (mean age 57 years) and compared to previously surgically managed 10 patients (26 rays) (mean age 59 years). Of all population, 51% for little, 47% for ring, 1% for middle and 1% for index fingers. The mean of the preintervention fixed flexion contracture in the MCP joint was 39º and improved to one-year postintervention 14º, and in the PIP joint 47º to 19º. In group B one ray with no improvement at all and recurrence in one ray. Partial stretching was achieved in one ray. No serious complications were observed after injections. In cases of group A (26 rays) that was treated by partial fasciectomy, recurrence occurred in 6 rays and nerve injuries as nerve division and neuropraxia occurred in 2 rays. Conclusion: The treatment of Dupuytren's disease with injectable collagenase is safe and effective. However, the financial aspects should be considered especially in developing | ||
| Keywords | ||
| Dupuytren finger collagenase Fasciectomy | ||
| References | ||
|
Shaw Jr. R.B., Chong A.K., Zhang A., Hentz V.R. and Chang J.: Dupuytren's disease: History, diagnosis, and treatment. J. Plastic Reconstructive Surgery, 120: 44e- 54e, 2007. 2- Townley W., Baker R., Sheppard N. and Grobbelaar A.: Dupuytren's contracture unfolded. J. B.M.J.: British Medical Journal, 332: 397, 2006. 3- Watt A.J., Curtin C.M. and Hentz V.R.: Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up. J. The Journal of hand surgery, 35: 534- 539. e531, 2010. 4- Gelbard M.K., James K., Riach P. and Dorey F.: Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J. The Journal of Urology, 149: 56-58, 1993. 5- Nydick J.A., Olliff B.W., Garcia M.J., Hess A.V. and Stone J.D.: A comparison of percutaneous needle fasciotomy and collagenase injection for Dupuytren disease. J. The Journal of Hand Surgery, 38: 2377-2380, 2013. 6- Peimer C.A., Blazar P., Coleman S., Kaplan F.T.D., Smith T. and Lindau T.: Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year 194 Vol. 43, No. 2 / Efficacy of Injectable Collagenase in the Treatment of Dupuytren's Contracture data. J. The Journal of Hand Surgery, 40: 1597-1605, 2015. 7- Skirven T.M., Bachoura A., Jacoby S.M., Culp R.W. and Osterman A.L.: The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by Dupuytren disease and treated with collagenase injection. J. The Journal of Hand Surgery, 38: 684-689, 2013. 8- Coleman S., Gilpin D., Kaplan F.T.D., et al.: Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J. The Journal of Hand Surgery, 39: 57-64, 2014. 9- Hovius S.E., Kan H.J., Smit X., Selles R.W., Cardoso E. and Khouri R.K.: Extensive percutaneous aponeurotomy and lipografting: A new treatment for Dupuytren disease. J. Plastic Reconstructive Surgery, 128: 221-228, 2011. 10- Van Rijssen A.L., Ter Linden H. and Werker P.M.: Fiveyear results of a randomized clinical trial on treatment in Dupuytren's disease: Percutaneous needle fasciotomy versus limited fasciectomy. J. Plastic Reconstructive Surgery, 129: 469-477, 2012. 11- Scherman P., Jenmalm P. and Dahlin L.: One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren's contracture: A two-centre prospective randomized clinical trial. J. Journal of Hand Surgery, 41: 577-582, 2016. 12- Desai S.S. and Hentz V.R.: Collagenase clostridium histolyticum for Dupuytren's contracture. J. Expert Opinion on Biological Therapy, 10: 1395-1404, 2010. 13- Warwick D., Arner M., Pajardi G., et al.: Collagenase Clostridium histolyticum in patients with Dupuytren's contracture: Results from POINT X, an open-label study of clinical and patient-reported outcomes. J. Journal of Hand Surgery, 40: 124-132, 2015. 14- Zhou, C., Hovius, S.E., Slijper, H.P., et al. Collagenase clostridium histolyticum versus limited fasciectomy for Dupuytren's contracture: outcomes from a multicenter propensity score matched study. J. Plastic Reconstructive Surgery, 136: 87-97, 2015. 15- Starkweather K.D., Lattuga S., Hurst L.C., et al.: Collagenase in the treatment of Dupuytren's disease: AN in vitro study. J. The Journal of Hand Surgery, 21: 490-495, 1996. 16- Badalamente M.A., Hurst L.C. and Hentz V.R.: Collagen as a clinical target: Nonoperative treatment of Dupuytren's disease. J. The Journal of Hand Surgery, 27: 788-798, 2002. 17- Peimer C., Wilbrand S., Gerber R., Chapman D. and Szczypa P.: Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture. J. Journal of Hand Surgery, 40: 141-9, 2015. 18- Chen N.C., Shauver M.J. and Chung K.C.: Costeffectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J. The Journal of Hand Surgery, 36: 1826-1834. e1832, 2011. 19- Atroshi I., Strandberg E., Lauritzson A., Ahlgren E. and Waldén M.: Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren's contracEgypt, J. Plast. Reconstr. Surg., July 2019 195 ture: A retrospective cohort study. J. B.M.J. open, 4: e004166, 2014. 20- Cerveró R.S., Ferrando N.F. and Jornet J.P.: Use of resources and costs associated with the treatment of Dupuytren's contracture at an orthopedics and traumatology surgery department in Denia (Spain): Collagenase clostridium hystolyticum versus subtotal fasciectomy. J. B.M.C. Musculoskeletal Disorders, 14: 293, 2013. 21- Peimer C.A., Blazar P., Coleman S., et al.: Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3- year data. J. The Journal of Hand Surgery, 38: 12-22, 2013. 22- Lipshultz L.I., Goldstein I., Seftel A.D., et al.: Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: Results from two large, double-blind, randomized, placebo-controlled, phase III studies, 116: 650-656, 2015. 23- Povlsen B. and Povlsen S.D.J.H.S.: What is the better treatment for single digit dupuytren's contracture: Surgical release or collagenase clostridium histolyticum (Xiapex) injection? 19: 389-392, 2014. | ||
|
Statistics Article View: 330 PDF Download: 622 |
||
